2. World Health Organization. HIV data and statistics 2023. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes

3. Покровский В.В, Ладная Н.Н., Соколова Е.В. ВИЧ-инфекция в Российской Федерации. 31 декабря 2022 года. www. hivrussia. info

Pokrovsky V.V., Ladnaia N.N., Sokolova E.V.

4. Titanji K., De Milito A., Kajigi A., Torstensson R., Grutsmayer S., Atlas A. et al. Loss of memory B cells impairs the maintenance of long-term serological memory during HIV-1 infection. Blood 2006; 108: 1580–7. DOI: 10.1182/blood-2005-11-013383

5. Janoff E.N., Breiman R.F., Daley K.L., Hopewell P.C. Pneumococcal disease in HIV infection. Epidemiological, clinical and immunological perspectives. Ann. Intern. Med. 1992; 117(4): 314–24. DOI: 10.7326/0003-4819-117-4-314

6. Heffernan R.T., Barrett N.L., Gallagher K.M., Hudler J.L., Harrison L.H., Reinhold A.L. et al. Reduction in the incidence of invasive Streptococcus pneumoniae infections among people with AIDS in the era of highly active antiretroviral therapy, 1995–2000. J. Infect. Dis. 2005; 191(12): 2038–45. DOI: 10.1086/430356

7. Saindou M., Chidiac S., Miaihes P., Voirin N., Baratin D., Amiri M. et al. Pneumococcal pneumonia in HIV-infected patients during periods of antiretroviral therapy. HIV Med. 2008; 9(4): 203–7. DOI: 10.1111/j.1468-1293.2008.00546.x

8. Yin Z., Rice B.D., Waight P., Miller E., George R., Brown A.E. et al. Invasive pneumococcal infection among HIV-positive individuals, 2000–2009. AIDS 2012; 26(1): 87–94. DOI: 10.1097/QAD.0b013e32834dcf27

9. Nunes M.C., Gottberg A.V., Gouveia L.D., Cohen C., Moore D.P., Klugman K.P. et al. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS 2011; 25(4): 453–62. DOI: 10.1097/QAD.0b013e328341b7f1

10. Heinsbroek E., Tafatatha T., Phiri A., Ngwira B., Crampin A.C., Read J.M. et al. Persisting high prevalence of pneumococcal carriage among HIV-infected adults receiving antiretroviral therapy in Malawi. AIDS 2015; 29(14): 1837–44. DOI: 10.1097/QAD.0000000000000755

11. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции. М.; 2016. 24 с.

[Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults]. Moscow; 2016. 24 p. (In Russ).

12. Weinberger D.M., Trzciński K., Lu Y.J., Bogaert D., Brandes A., Galagan J. et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 2009; 5(6): e1000476. DOI: 10.1371/journal. ppat.1000476

13. Scott J.A., Hall A.J., Dagan R., Dixon J.M., Eykyn S.J., Fenoll A. et al. Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. Clin. Infect. Dis. 1996; 22(6): 973–81. DOI: 10.1093/clinids/22.6.973

14. Намазова-Баранова Л.С., Федосеенко М.В., Вишнева Е.А. Теоретические основы и реальные результаты: обзор материалов по вакцинопрофилактике пневмококковой инфекции в мире. Педиатрическая фармакология 2018; 15(1): 58–74. doi: 10.15690/ pf.v15i1.1844

Namazova-Baranova L.S., Fedoseenko M.V., Vishnyova E.A.

15. Fletcher M.A., Schmitt H.J., Syrochkina M., Sylvester G. Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology. Eur. J. Clin. Microbiol. Infect. Dis. 2014; 33(6): 879–910. DOI: 10.1007/s10096-014-2062-6

16. Баранов А.А., Намазова-Баранова Л.С., Брико Н.И., Лобзин Ю.В., Козлов Р.С., Костинов М.П. и др. Вакцинопрофилактика пневмококковой инфекции у детей. Педиатрическая фармакология 2018; 15(3): 200–11. DOI: 10.15690/pf.v15i3.1899

Baranov A.A., Namazova-Baranova L.S., Briko N.I., Lobzin Yu.V., Kozlov R.S., Kostinov M.P et al.

17. Драпкина О.М., Брико Н.И., Костинов М.П., Фельдблюм И.В., Алыева М.Х., Андреева Н.П. и др. Иммунизация взрослых. Методические рекомендации. М., 2020. 248 с.

Drapkina O.M., Briko N.I., Kostinov M.P., Feldblum I.V., Alyeva M.Kh., Andreeva N.P. et al.

18. McLaughlin J., Jiang Q., Isturiz R.E., Sings H.L., Swerdlow D.L., Gessner B.D. et al. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clin. Infect. Dis. 2018; 67(10): 1498–1506. DOI: 10.1093/cid/ciy312

19. French N., Gordon S.B., Mwalukomo T., White S.A., Mwafulirwa G., Longwe H. et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N. Engl. J. Med. 2010; 362: 812–22. DOI: 10.1056/NEJMoa0903029

20. Ibarz-Pavon A.B., French N. No changes on viral load and CD4+ T-cell counts following immunization with 7-valent pneumococcal conjugate vaccine among HIV-infected adults in Malawi. Vaccine 2018; 36: 2504–6. DOI: 10.1016/j.vaccine.2018.04.009

21. McLaughlin J.M., Swerdlow D.L., Isturiz R.E., Jodar L. Decision-making for PCV in adults. Hum. Vaccin Immunother. 2019; 15: 584–93. DOI: 10.1080/21645515.2018.1538611

22. Pedersen R.H., Lohes N., Østergaard L., Søgaard O.S. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Medicine 2011; 12: 323–33. DOI: 10.1111/j.1468-1293.2010.00892.x

23. Crum-Cianflone N.F., Hullsiek K.H., Roediger M., Ganesan A., Patel S., Landrum M.L. et al. A randomized clinical trial comparing the revaccination of pneumococcal conjugate vaccine with polysaccharide vaccine among HIV-infected adults. J. Infect. Dis. 2010; 202: 1114–25. DOI: 10.1086/656147

24. Cordonnier C., Averbuch D., Maury S., Engelhard D. Pneumococcal immunization in immunocompromised hosts: where do we stand? Expert Rev. Vaccines. 2014; 13: 59–74. DOI: 10.1586/14760584.2014.859990

25. Feikin D.R., Elie C.M., Goetz M.B., Lennox J.L., Carlone G.M., Romero-Steiner S. et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001; 20: 545–53. DOI: 10.1016/s0264-410x(01)00347-4

26. Miiro G., Kayhty H., Watera C., Tolmie H., Whitworth J.A.M., Gilks C.F. et al. Conjugate pneumococcal vaccine in HIV-infected ugandans and the effect of past receipt of polysaccharide vaccine. J. Infect Dis. 2005; 192: 1801–5. DOI: 10.1086/497144

27. Sadlier C., O’Dea S., Bennett K., Dunne J., Conlon N., Bergin C. Immunological efficacy of pneumococcal vaccine strategies in HIV-infected adults: a randomized clinical trial. Sci. Rep. 2016; (6): 32076. DOI: 10.1038/srep32076

28. Grau I., Pallares R., Tubau F., Schulze M.H., Llopis F., Podzamczer D. et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch. Intern. Med. 2005; 165: 1533–40. DOI: 10.1001/archinte.165.13.1533

29. Hung C.C., Chen M.Y., Hsieh S.M., Hsiao C.F., Sheng W.H., Chang S.C. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004; 22: 2006–12. DOI: 10.1016/j.vaccine.2003.10.030

30. Watera C., Nakiyingi J., Miiro G., Muwonge R., Whitworth J.A.G., Gilks C.F. et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004; 18: 1210–13. DOI: 10.1097/00002030-200405210-00018

31. Hung C.-C., Chang S.-Y., Su C.-T., Chen Y.-Y., Chang S.-F., Yang C.-Y. et al. A 5-year longitudinal follow-up study of serological reactions to vaccination with 23-valent pneumococcal polysaccharide among HIV-infected patients receiving highly active antiretroviral therapy. HIV Med. 2010; 11: 54–63. DOI: 10.1111/j.1468-1293.2009.00744.x

32. Whitaker J.A., Rouphael N.G.., Edupuganti S, Lai L., Mulligan M.J. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect. Dis. 2012; (12): 966–76. DOI: 10.1016/S1473-3099(12)70243-8

33. Tasker S.A., Wallace M.R., Rubins J.B., Paxton W.B., O’Brien J., Yanoff E.N. Repeated immunization with 23-valent pneumococcal vaccine in patients infected with human immunodeficiency virus type 1: clinical, immunological and virological responses. Clin. Infect. Dis. 2002; 34: 813–21. DOI: 10.1086/339044

34. British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015. http://www.bhiva.org/documents/Guidelines/Immunisation/ consultation/BHIVA-Immunisation-Guidelines-2015-Consultation.pdf

35. ACIP: General Best Practice Guidelines for Immunization: Altered Immunocompetence. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html

36. The European Clinical AIDS Society (EACS) Guidelines for HIV Treatment. Version 8.2. January 2017. http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html

37. Aberg J.A., Gallant J.E., Ghanem K.G., Emmanuel P., Zingman B.S., Horberg M.A. Recommendations for primary care for people infected with HIV: 2013 update prepared by the Association of HIV Medicine of the American Society of Infectious Diseases. A clinical case of infection. 2014; 58(1): e1–34. DOI: 10.1093/cid/cit665

38. Frazard A., Gagnier-Brunon A., Lucht F., Botelho-Nevers E., Lone O. Immunization of HIV-infected adult patients – French recommendations. Enzyme immunoassay gum vaccine. Hum. Vaccin Immunother. 2016; (12): 2729–41. DOI: 10.1080/21645515.2016.1207013

39. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Буравцова Е.В., Деулина М.О. и др. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ. Эпидемиол. инфекц. болезни. Актуал. вопр. 2023; 12(4, приложение). 109 с.

Pokrovsky V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Buravtsova E.V., Deulina M.O. et al.

40. Glesby M.J., Watson W., Brinson C., Greenberg R.N., Lalezari J.P., Skiest D. et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with pneumococcal polysaccharide vaccine. J. Infect Dis. 2015; 212: 18–27. DOI: 10.1093/ infdis/jiu631